We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Valneva SE began production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in an effort to optimize the timeline for potential deliveries of the vaccine.